BACKGROUND There are many adverse reactions in the treatment of allergic rhinitis(AR)mainly with conventional drugs.Leukotriene receptor antagonists,glucocorticoids and nasal antihistamines can all be used as first-li...BACKGROUND There are many adverse reactions in the treatment of allergic rhinitis(AR)mainly with conventional drugs.Leukotriene receptor antagonists,glucocorticoids and nasal antihistamines can all be used as first-line drugs for AR,but the clinical effects of the three drugs are not clear.AIM To examine the impact of glucocorticoids,antihistamines,and leukotriene receptor antagonists on individuals diagnosed with AR,specifically focusing on their influence on serum inflammatory indexes.METHODS The present retrospective study focused on the clinical data of 80 patients diagnosed and treated for AR at our hospital between May 2019 and May 2021.The participants were categorized into the control group and the observation group.The control group received leukotriene receptor antagonists,while the observation group was administered glucocorticoids and antihistamines.Conducted an observation and comparison of the symptoms,physical sign scores,adverse reactions,and effects on serum inflammatory indexes in two distinct groups of patients,both before and after treatment.RESULTS Subsequent to treatment,the nasal itching score,sneeze score,runny nose score,nasal congestion score,and physical signs score exhibited notable discrepancies(P<0.05),with the observation group demonstrating superior outcomes compared to the control group(P<0.05).The interleukin(IL)-6,IL-10,tumor necrosis factor-alpha,Soluble Intercellular Adhesion Molecule-1,Leukotriene D4 after treatment were significantly different and the observation group It is better than the control group,which is statistically significant(P<0.05).Following the intervention,the incidence of adverse reactions in the observation group,including symptoms such as nasal dryness,discomfort in the throat,bitter taste in the mouth,and minor erosion of the nasal mucosa,was found to be 7.5%.This rate was significantly lower compared to the control group,which reported an incidence of 27.5%.The difference between the two groups was statistically significant(P<0.05).CONCLUSION Glucocorticoids and antihistamines have obvious therapeutic effects,reduce serum inflammatory index levels,relieve symptoms and signs of patients,and promote patients'recovery,which can provide a reference for clinical treatment of AR.展开更多
Objectives To assess the hemodynamic, oxygen-dynamic and ventilative effects of Zafirlukast in chronic obstructive pulmonary disease (COPD) induced chronic cor pulmonale at acute exacerbation stage and the mechanisms ...Objectives To assess the hemodynamic, oxygen-dynamic and ventilative effects of Zafirlukast in chronic obstructive pulmonary disease (COPD) induced chronic cor pulmonale at acute exacerbation stage and the mechanisms of Zafirlukast efficacy.Methods Eleven cases of chronic cor pulmonale at acute exacerbation were examinted using Swan-Ganz catheter and peripheral intra-artery catheter. The hemodynamic, oxygen-dynamic parameters and respiratory rate, plasma endothelium-1 (ET-1) level, and urea leukotriene E4 (LTE4) level were measured before and at the 1st, 3rd, 5th, 7th, 9th, 12th hour after taking 40 mg Zafirlukast orally. Artarial and mixed venous blood gas analyses were done correspondingly.Results The average pulmonary arterial pressure (mPAP) and pulmonary vascular resistance index (PVRI) were lowered at the 3rd hour after taking Zafirlukast by 23% and 36.5%, respectively. They returned to the baseline around 12th hour. Respiratory rate decreased significantly within the 3rd-7th hour after taking Zafirlukast. LTE4 and ET-1 levels lowered at the 3rd hour and showed a positive correlation with change of mPAP. Conclusions Zafirlukast can reduce mPAP, pulmonary vascular resistance (PVR) and does not affect the ambulatory blood pressure monitoring (ABPM) and oxygenation in cases of chronic cor pulmonale at acute exacerbation stage. Zafirlukast may play a role as an alternative to decrease PAP in COPD patients.展开更多
目的观察儿童轻中度阻塞性睡眠呼吸暂停低通气综合征(OS A H S)抗炎治疗的临床疗效,分析儿童OSAHS与炎症的关系。方法选取2016年1-11月经多导睡眠监测(PSG)确诊的轻中度OSAHS患儿50例,记录病史、腺样体大小、扁桃体大小、OSA-18问卷评分...目的观察儿童轻中度阻塞性睡眠呼吸暂停低通气综合征(OS A H S)抗炎治疗的临床疗效,分析儿童OSAHS与炎症的关系。方法选取2016年1-11月经多导睡眠监测(PSG)确诊的轻中度OSAHS患儿50例,记录病史、腺样体大小、扁桃体大小、OSA-18问卷评分,给予糠酸莫米松鼻喷剂联合口服孟鲁司特治疗12周,治疗结束后复查PSG、腺样体大小、扁桃体大小及OSA-18问卷,并对治疗前后的数据进行比较。结果在50例患儿中,轻度OSAHS37例,中度OSAHS 13例;共治愈19例(38%),其中轻度OSAHS 17例,中度OSAHS 2例;显效14例(28%);有效5例(10%);总体有效率为76%(38/50)。与治疗前比较,轻度OSAHS患儿治疗后阻塞性呼吸暂停指数(OAI)、混合性呼吸暂停指数(MAI)降低,腺样体、扁桃体体积缩小,OSA-18评分降低,差异均有统计学意义(P<0.05)。中度OSAHS患儿治疗后OAI较治疗前明显降低(P<0.05),而腺样体、扁桃体体积及OSA-18评分、MAI与治疗前比较差异无统计学意义(P>0.05)。扁桃体体积变化与PSG参数变化无明显相关性。结论抗炎治疗可明显改善OSAHS患儿的PSG指数、腺样体和扁桃体体积及生活质量,对轻度OSAHS患儿疗效更为显著。展开更多
文摘BACKGROUND There are many adverse reactions in the treatment of allergic rhinitis(AR)mainly with conventional drugs.Leukotriene receptor antagonists,glucocorticoids and nasal antihistamines can all be used as first-line drugs for AR,but the clinical effects of the three drugs are not clear.AIM To examine the impact of glucocorticoids,antihistamines,and leukotriene receptor antagonists on individuals diagnosed with AR,specifically focusing on their influence on serum inflammatory indexes.METHODS The present retrospective study focused on the clinical data of 80 patients diagnosed and treated for AR at our hospital between May 2019 and May 2021.The participants were categorized into the control group and the observation group.The control group received leukotriene receptor antagonists,while the observation group was administered glucocorticoids and antihistamines.Conducted an observation and comparison of the symptoms,physical sign scores,adverse reactions,and effects on serum inflammatory indexes in two distinct groups of patients,both before and after treatment.RESULTS Subsequent to treatment,the nasal itching score,sneeze score,runny nose score,nasal congestion score,and physical signs score exhibited notable discrepancies(P<0.05),with the observation group demonstrating superior outcomes compared to the control group(P<0.05).The interleukin(IL)-6,IL-10,tumor necrosis factor-alpha,Soluble Intercellular Adhesion Molecule-1,Leukotriene D4 after treatment were significantly different and the observation group It is better than the control group,which is statistically significant(P<0.05).Following the intervention,the incidence of adverse reactions in the observation group,including symptoms such as nasal dryness,discomfort in the throat,bitter taste in the mouth,and minor erosion of the nasal mucosa,was found to be 7.5%.This rate was significantly lower compared to the control group,which reported an incidence of 27.5%.The difference between the two groups was statistically significant(P<0.05).CONCLUSION Glucocorticoids and antihistamines have obvious therapeutic effects,reduce serum inflammatory index levels,relieve symptoms and signs of patients,and promote patients'recovery,which can provide a reference for clinical treatment of AR.
文摘Objectives To assess the hemodynamic, oxygen-dynamic and ventilative effects of Zafirlukast in chronic obstructive pulmonary disease (COPD) induced chronic cor pulmonale at acute exacerbation stage and the mechanisms of Zafirlukast efficacy.Methods Eleven cases of chronic cor pulmonale at acute exacerbation were examinted using Swan-Ganz catheter and peripheral intra-artery catheter. The hemodynamic, oxygen-dynamic parameters and respiratory rate, plasma endothelium-1 (ET-1) level, and urea leukotriene E4 (LTE4) level were measured before and at the 1st, 3rd, 5th, 7th, 9th, 12th hour after taking 40 mg Zafirlukast orally. Artarial and mixed venous blood gas analyses were done correspondingly.Results The average pulmonary arterial pressure (mPAP) and pulmonary vascular resistance index (PVRI) were lowered at the 3rd hour after taking Zafirlukast by 23% and 36.5%, respectively. They returned to the baseline around 12th hour. Respiratory rate decreased significantly within the 3rd-7th hour after taking Zafirlukast. LTE4 and ET-1 levels lowered at the 3rd hour and showed a positive correlation with change of mPAP. Conclusions Zafirlukast can reduce mPAP, pulmonary vascular resistance (PVR) and does not affect the ambulatory blood pressure monitoring (ABPM) and oxygenation in cases of chronic cor pulmonale at acute exacerbation stage. Zafirlukast may play a role as an alternative to decrease PAP in COPD patients.
文摘目的观察儿童轻中度阻塞性睡眠呼吸暂停低通气综合征(OS A H S)抗炎治疗的临床疗效,分析儿童OSAHS与炎症的关系。方法选取2016年1-11月经多导睡眠监测(PSG)确诊的轻中度OSAHS患儿50例,记录病史、腺样体大小、扁桃体大小、OSA-18问卷评分,给予糠酸莫米松鼻喷剂联合口服孟鲁司特治疗12周,治疗结束后复查PSG、腺样体大小、扁桃体大小及OSA-18问卷,并对治疗前后的数据进行比较。结果在50例患儿中,轻度OSAHS37例,中度OSAHS 13例;共治愈19例(38%),其中轻度OSAHS 17例,中度OSAHS 2例;显效14例(28%);有效5例(10%);总体有效率为76%(38/50)。与治疗前比较,轻度OSAHS患儿治疗后阻塞性呼吸暂停指数(OAI)、混合性呼吸暂停指数(MAI)降低,腺样体、扁桃体体积缩小,OSA-18评分降低,差异均有统计学意义(P<0.05)。中度OSAHS患儿治疗后OAI较治疗前明显降低(P<0.05),而腺样体、扁桃体体积及OSA-18评分、MAI与治疗前比较差异无统计学意义(P>0.05)。扁桃体体积变化与PSG参数变化无明显相关性。结论抗炎治疗可明显改善OSAHS患儿的PSG指数、腺样体和扁桃体体积及生活质量,对轻度OSAHS患儿疗效更为显著。
